Cantharidin

Introduction Overview

Generic Name

cantharidin

Brand Name

Ycanth

Dosage Form

topical solution

Drug Class

Topical keratolytics

Pharmacokinetics

Absorption:
Cantharidin applied topically as Ycanth is primarily absorbed locally at the site of application. Due to its vesicant nature and keratolytic properties, systemic absorption is minimal when applied correctly by healthcare providers. The drug’s absorption is limited by its topical route and the controlled, small application volume. However, inadvertent ingestion or application to mucous membranes significantly increases systemic exposure, leading to life-threatening toxicity.

Distribution:
The distribution of cantharidin following topical application is largely localized within the epidermis and upper dermis where it exerts its keratolytic and vesicant action. In cases of systemic absorption, cantharidin disperses in the bloodstream and distributes to highly vascularized organs, including the kidneys and gastrointestinal tract, where toxic effects can manifest. However, detailed pharmacokinetic distribution data for topical cantharidin are limited.

Metabolism:
Cantharidin is metabolized primarily in the liver through hydrolysis and other enzymatic processes to inactive metabolites. Its metabolic pathway in humans is not fully characterized but is believed to involve cytochrome P450 enzymes. Due to the topical application and minimal systemic absorption under proper use, hepatic metabolism plays a minor role clinically in Ycanth treatment.

Elimination:
Elimination occurs predominantly through renal excretion of cantharidin metabolites. The exact half-life is not established in humans for topical use, but systemic toxicity data indicate renal clearance is a significant route for cantharidin elimination. Monitoring renal function is important in cases of accidental ingestion or exposure to avoid accumulation and systemic toxicity.

Dosage Forms

Available Dosage Forms:
Ycanth is available as a topical solution containing 0.7% cantharidin formulated for cutaneous application by healthcare providers.

Dosages for Adults and Adolescents:
Ycanth is administered as a topical single application by a healthcare provider to the affected skin areas exhibiting molluscum contagiosum lesions. Treatment is repeated every 3 weeks as needed based on clinical response and lesion clearance. The exact volume applied is controlled and directed to the lesions, minimizing exposure to surrounding skin.

Specific Patient Populations:
Ycanth is approved for use in adults and children aged 2 years and older. Safety and efficacy in children under 2 years have not been established. Caution is advised in patients with skin conditions or sensitivity in treated areas. It is not to be applied to mucous membranes, eyes, or genital regions to avoid severe local and systemic adverse effects.

The product includes a violet-colored dye to help visualize application areas and contains a bittering agent, denatonium benzoate, to discourage accidental ingestion, especially by children.

Mechanism Of Action

Cantharidin, the active component of Ycanth, is a potent vesicant agent that induces blister formation through its action as a protein phosphatase inhibitor, particularly targeting PP2A and PP1 enzymes. This inhibition disrupts cellular signaling pathways and cytoskeletal integrity, leading to the separation of the epidermal layers and vesicle (blister) formation.

At the cellular level, cantharidin causes keratinocyte degeneration and the release of intracellular enzymes that facilitate detachment of the stratum corneum, effectively producing a keratolytic effect. This mechanism facilitates sloughing of infected skin cells, thereby removing molluscum contagiosum lesions.

The biochemical interactions entail the disruption of protein phosphatase-mediated signaling pathways responsible for cell adhesion and survival, inducing apoptosis and localized necrosis of infected epidermal cells. This localized cytotoxicity aids in eliminating the viral-infected lesions while sparing surrounding healthy tissue when applied judiciously.

Clinically, this mechanism translates into the controlled destruction and clearance of molluscum contagiosum lesions observed after Ycanth application. Compared to other topical keratolytics, such as salicylic acid or podophyllotoxin, cantharidin’s unique vesicant effect offers a direct blistering action that promotes lesion resolution. Clinical studies have demonstrated effectiveness in both pediatric and adult populations with a manageable safety profile when used under proper medical supervision.

Pharmacological Actions

Induces blister formation through vesicant action.
Inhibits protein phosphatases PP2A and PP1, disrupting intracellular signaling.
Keratolytic activity causing detachment of the stratum corneum.
Promotes localized apoptosis and necrosis of infected epidermal cells.
Facilitates removal of molluscum contagiosum lesions by epidermal exfoliation.
Minimal systemic absorption when applied topically according to guidelines.
Exerts localized cytotoxic effect without systemic antiviral activity.
Contains bittering agent to prevent accidental ingestion.
Formulated with a dye for visualizing treatment area.
Non-steroidal topical agent with no known hormonal activity.
Does not interfere with systemic immune function.
Relatively rapid onset of action with lesion improvement typically after one or multiple treatments.
Protects healthy skin by limited application and controlled use by healthcare providers.
Flammable formulation necessitating avoidance of fire or flame during treatment.

Therapeutic Or Clinical Uses

Treatment of molluscum contagiosum in adults and children aged 2 years and older.
Facilitates removal of molluscum lesions causing pain, itching, or bacterial superinfection.
Management of viral skin lesions not responsive to other topical modalities.
Recommended for patients with multiple molluscum lesions unsuitable for cryotherapy or curettage.
Used when rapid lesion clearance is desired, with treatments repeated every 3 weeks as needed.
Topical option for patients who cannot tolerate or have contraindications to other antiviral or keratolytic agents.
Applied under medical supervision to reduce risks of complications and optimize outcomes.
Considered in clinical guidelines as an effective topical keratolytic for viral skin disease.
May be used in pediatric dermatology settings due to safety profile established in children ≥2 years.
Adjunct to other skin care measures for molluscum contagiosum management.
Off-label use is not currently established; strictly indicated for molluscum contagiosum only.
Used when lesion localization allows safe topical application avoiding mucous membranes and eyes.
Promotes lesion drying and detachment reducing transmission risk.
Avoided in areas prone to secondary infection or irritation.

Side Or Adverse Effects

Local vesiculation and blister formation at the application site.
Pain and burning sensation at treated areas.
Pruritus (itching) in and around treated skin lesions.
Erythema (skin redness) localized to treated areas.
Skin discoloration including hypo- or hyperpigmentation at treatment sites.
Crusting, scabbing, and dry skin over treated lesions.
Swelling and inflammation near the application area.
Breakdown or erosion of epidermal layers resulting in superficial skin injury.
Severe blistering or painful reactions requiring premature washing off the product.
Rare systemic toxicity if accidentally ingested or applied to mucous membranes.
Potential severe eye injury including corneal ulceration and permanent damage if exposure occurs.
Risk of secondary bacterial infection of blistered skin if not properly managed.
Possible allergic reactions in patients sensitive to cantharidin or inactive ingredients.
Transient staining of the skin from violet dye contained in the solution.
Flammability risk of the product during and shortly after application.

Precautions

Only to be applied by healthcare professionals trained in Ycanth application.
Avoid application on mucous membranes including eyes, mouth, genitalia, and nose.
Protect treated areas from contact with mouth and eyes for at least 24 hours.
Do not apply to healthy skin; confined solely to molluscum contagiosum lesions.
Avoid use in patients with known hypersensitivity or allergy to cantharidin or excipients.
Avoid concomitant use of topical steroids, creams, lotions, or sunscreen on treated areas until product is washed off.
Monitor for severe skin reactions; wash off earlier than 24 hours if severe blistering or pain occurs.
Prevent exposure of treated sites to fire, flame, or smoking due to flammability.
Exercise caution in pregnant or breastfeeding patients; discuss risks and benefits prior to use.
Prevent children from licking or biting treated skin to avoid accidental ingestion.
Patients should report any severe pain, swelling, or unusual skin reactions promptly.
Ensure safe storage away from children and untrained individuals to prevent misuse.
Do not bandage treated areas to prevent occlusion which can increase absorption and irritation.
Apply with appropriate personal protective equipment to avoid inadvertent exposure.
Avoid use in children under 2 years old due to unknown safety profile.

Warnings

Life-threatening or fatal toxicities can occur if Ycanth is ingested or enters systemic circulation.
Avoid contact of the solution with eyes and mucous membranes to prevent severe injury.
Severe local skin reactions such as intense blistering, pain, and erythema can occur.
Remove product immediately if severe reactions occur before the 24-hour contact period ends.
Ycanth is highly flammable even after drying; avoid fire, flames, or smoking during treatment.
Accidental oral ingestion may cause kidney failure, gastrointestinal damage, seizures, and paralysis.
Serious eye injury including blindness possible if the product contacts eyes.
Avoid use near eyes or mouth due to risk of accidental exposure and toxicity.
Keep treated areas away from children’s hands to minimize risk of accidental ingestion or eye exposure.
Promptly flush eyes with water for at least 15 minutes if accidental exposure occurs and seek emergency care.
Risk of blood clotting abnormalities reported following accidental ingestion.
Not established as safe during pregnancy; use only if benefits justify potential risks.
Safety in children under 2 years has not been established; use contraindicated in this age group.
Do not use on areas with active skin infection or ulceration to prevent exacerbation.
Failure to follow application instructions may increase risk of severe adverse outcomes.

Contraindication

Known allergy or hypersensitivity to cantharidin or any inactive ingredients in Ycanth formulation.
Application to mucous membranes including eyes, mouth, genitalia, or nasal mucosa is contraindicated.
Use in children under 2 years of age due to lack of safety and efficacy data.
Avoid use over areas of broken or compromised skin not affected by molluscum contagiosum.
Patients with a history of severe skin reactions to topical keratolytics.
Patients with active secondary skin infection at intended treatment sites.
Known flammability precautions contraindicate use in environments with risk of fire exposure.
Contraindicated in patients unable to comply with treatment precautions to avoid accidental ingestion or ocular exposure.
Not indicated for other viral or dermatological conditions outside of molluscum contagiosum.
Use contraindicated if prior adverse reactions to scented or dye-containing topical preparations.
Severe hypersensitivity reactions including anaphylaxis to any component contraindicate re-exposure.
Use avoided in pregnancy and lactation unless clearly indicated and supervised.
Contraindicated when concurrent use of interfering topical agents like steroids is unavoidable.
Patients with severe dermatological conditions that may exacerbate with keratolytic agents.
Patients with impaired renal function at risk of systemic accumulation if accidental ingestion occurs.

Drug Interactions

No formal studies evaluating drug interactions with cantharidin have been conducted.
Concurrent application with topical steroids, creams, lotions, or sunscreens is not recommended and should be avoided for 24 hours after treatment.
Potential increased irritation or reduced efficacy if combined with other topical keratolytics.
No known systemic drug interactions due to minimal systemic absorption with topical application.
Avoid use of occlusive dressings post-application to prevent increased absorption and interactions.
No documented interactions with systemic antivirals or immunomodulatory drugs.
Potential additive local irritation if co-administered with other vesicant or irritant topical agents.
No reported interactions with common dermatological emollients that do not alter skin barrier significantly.
Concurrent use with oral medications does not appear to alter pharmacokinetics or dynamics of cantharidin.
Patient counseling should include avoidance of any other topical skin products on treated areas until washing off Ycanth.
Herbal or complementary topical remedies should be avoided during treatment to prevent unpredictable interactions.
Providers should inform patients about avoiding other topical agents for at least 24 hours post application.
No documented interaction with systemic drugs metabolized by cytochrome P450 enzymes due to minimal systemic absorption.
No evidence suggests interaction with vaccination or immunotherapy agents.
Caution advised when using Ycanth in patients receiving systemic immunosuppressants, although no direct interactions are expected.

Preparations Of The Drug

Ycanth is supplied as a 0.7% cantharidin topical solution for cutaneous application.
Contains inactive ingredients: acetone, camphor, castor oil, denatonium benzoate (bittering agent), ethanol, gentian violet dye, hydroxypropyl cellulose, and nitrocellulose.
Formulated with a violet-colored dye to aid visualization of treated lesions during application.
Denatonium benzoate included to discourage accidental ingestion by imparting bitter taste.
Packaged in single-use or multi-use containers for application by healthcare providers with appropriate PPE.
Storage conditions recommend 20°C to 25°C with excursions between 15°C and 30°C; protect from light exposure.
Flammable formulation requiring storage and handling away from flames, sparks, or heat sources.
Applied with gloves and personal protective equipment, including eye protection to avoid inadvertent exposure.
No formulations intended for over-the-counter use; prescription and administration strictly by medical professionals.
Not available in alternate dosage forms such as creams, gels, or patches.
No oral or systemic preparations are available due to toxicity profile of cantharidin.
The solution dries within approximately 5 minutes post application for safe patient discharge.
No combination products with other active ingredients marketed under Ycanth brand.
Manufactured by Verrica Pharmaceuticals, Inc., ensuring quality and stability under recommended storage.
Instructions emphasize avoiding topical concomitant products on treated areas until washing off.